Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Lahat, E.
Right arrow Articles by Ron-El, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lahat, E.
Right arrow Articles by Ron-El, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 14, No. 10, 2656-2660, October 1999
© 1999 European Society of Human Reproduction and Embryology

Long-term follow-up of children born after inadvertent administration of a gonadotrophin-releasing hormone agonist in early pregnancy

E. Lahat2,3, A. Raziel1, S. Friedler1, M. Schieber-Kazir2 and R. Ron-El1

1 Departments of Obstetrics and Gynecology, and 2 Pediatric Neurology, Assaf Harofeh Medical Center, affiliated to Sackler Faculty of Medicine, Tel Aviv University, Israel

Our objective was to evaluate long-term outcome of children born after inadvertent administration of a gonadotrophin-releasing hormone agonist (GnRHa) in early pregnancy, compared to a control group of children born to matched women undergoing in-vitro fertilization and children born after spontaneous pregnancies. Six children from six pregnancies, exposed to a long-acting gonadotrophin agonist, comprised the study group and 20 children were included in the control groups. Pre-, peri- and postnatal data were collected and the children were followed and examined at a mean age of 7.8 ± 2.0 years. All children underwent physical and neurological examination, and psychological tests. In the study group, one child was born with a major congenital malformation (cleft palate), and four children subsequently demonstrated neurodevelopmental abnormalities, including epileptic disorder (n = 1), attention deficit hyperactivity disorder (n = 3), motor difficulties (n = 3) and speech difficulties (n = 1). In the control groups, one child had attention deficit hyperactivity disorder. This observation of neurodevelopmental abnormalities in four of six children in the study group justifies the need for long-term follow-up of more children previously exposed to gonadotrophin-releasing hormone agonist.

Key words: GnRHa/pregnancy

3 To whom correspondence should be addressed at: Pediatric Neurology Unit, Assaf Harofeh Medical Center, Zerifin 70300, Israel


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
M. Hansen, C. Bower, E. Milne, N. de Klerk, and J. J.Kurinczuk
Assisted reproductive technologies and the risk of birth defects--a systematic review
Hum. Reprod., February 1, 2005; 20(2): 328 - 338.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
P. Platteau, M. Vandervorst, and P. Devroey
Long term follow-up of children born after inadvertent administration of a GnRH-analogue in early pregnancy
Hum. Reprod., June 1, 2000; 15(6): 1421 - 1421.
[Full Text] [PDF]

Home page
 Hum ReprodHome page
E. Lahat and R. Ron-El

Hum. Reprod., June 1, 2000; 15(6): 1421 - 1421.
[Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.